Manning & Napier Advisors LLC Has $30.13 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Manning & Napier Advisors LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 326,137 shares of the biopharmaceutical company's stock after selling 28,444 shares during the quarter. Manning & Napier Advisors LLC's holdings in Gilead Sciences were worth $30,125,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences during the third quarter worth about $25,000. Valued Wealth Advisors LLC lifted its position in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 161 shares during the period. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the fourth quarter worth about $29,000. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences in the 2nd quarter valued at about $33,000. Finally, Quarry LP acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at about $43,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 over the last 90 days. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded up $1.36 during trading on Thursday, hitting $96.95. 5,017,406 shares of the stock were exchanged, compared to its average volume of 6,704,090. The stock's fifty day moving average is $92.14 and its 200 day moving average is $85.51. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The stock has a market cap of $120.83 billion, a PE ratio of 1,077.22, a P/E/G ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.29 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on GILD shares. Morgan Stanley upgraded shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $87.00 to $113.00 in a report on Friday, January 10th. Barclays upped their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Thursday, November 7th. Truist Financial lifted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research note on Friday, November 8th. Wolfe Research started coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an "outperform" rating and a $110.00 target price for the company. Finally, Piper Sandler lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.